Selected research
Industry Research
Oncolytic Virus Service Industry Research Report 2026
Market perspective
The global Oncolytic Virus Service market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Oncolytic Virus Service market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Oncolytic Virus Service market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Oncolytic Virus Service market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Oncolytic Virus Service include Creative Biolabs, Creative Biogene, Recipharm, Nabios, IDT Biologika, FUJIFILM Diosynth Biotechnologies, Exothera, Lonza and ABL, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Oncolytic Virus Service market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Oncolytic Virus Service.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Oncolytic Virus Service Market by Company
Creative Biolabs
Creative Biogene
Recipharm
Nabios
IDT Biologika
FUJIFILM Diosynth Biotechnologies
Exothera
Lonza
ABL
Takara Bio
Libentech
Oncolytic Virus Service Segment by Type
Measles Virus (MeV)
Herpes Simplex Virus (HSV-1)
Others
Oncolytic Virus Service Segment by Application
Tumor Treatment
Scientific Research
Oncolytic Virus Service Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oncolytic Virus Service market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Oncolytic Virus Service and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oncolytic Virus Service.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Oncolytic Virus Service companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Measles Virus (MeV)
- Herpes Simplex Virus (HSV-1)
- Others
Applications
- Tumor Treatment
- Scientific Research
Companies covered
- Creative Biolabs
- Creative Biogene
- Recipharm
- Nabios
- IDT Biologika
- FUJIFILM Diosynth Biotechnologies
- Exothera
- Lonza
- ABL
- Takara Bio
- Libentech
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Oncolytic Virus Service by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Measles Virus (MeV)
- 2.2.3 Herpes Simplex Virus (HSV-1)
- 2.2.4 Others
- 2.3 Oncolytic Virus Service by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Tumor Treatment
- 2.3.3 Scientific Research
- 2.4 Assumptions and Limitations
3 Oncolytic Virus Service Breakdown Data by Type
- 3.1 Global Oncolytic Virus Service Historic Market Size by Type (2021-2026)
- 3.2 Global Oncolytic Virus Service Forecasted Market Size by Type (2027-2032)
4 Oncolytic Virus Service Breakdown Data by Application
- 4.1 Global Oncolytic Virus Service Historic Market Size by Application (2021-2026)
- 4.2 Global Oncolytic Virus Service Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Oncolytic Virus Service Market Perspective (2021-2032)
- 5.2 Global Oncolytic Virus Service Growth Trends by Region
- 5.2.1 Global Oncolytic Virus Service Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Oncolytic Virus Service Historic Market Size by Region (2021-2026)
- 5.2.3 Oncolytic Virus Service Forecasted Market Size by Region (2027-2032)
- 5.3 Oncolytic Virus Service Market Dynamics
- 5.3.1 Oncolytic Virus Service Industry Trends
- 5.3.2 Oncolytic Virus Service Market Drivers
- 5.3.3 Oncolytic Virus Service Market Challenges
- 5.3.4 Oncolytic Virus Service Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Oncolytic Virus Service Players by Revenue
- 6.1.1 Global Top Oncolytic Virus Service Players by Revenue (2021-2026)
- 6.1.2 Global Oncolytic Virus Service Revenue Market Share by Players (2021-2026)
- 6.2 Global Oncolytic Virus Service Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Oncolytic Virus Service Head Office and Area Served
- 6.4 Global Oncolytic Virus Service Players, Product Type & Application
- 6.5 Global Oncolytic Virus Service Manufacturers Established Date
- 6.6 Global Oncolytic Virus Service Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Oncolytic Virus Service Market Size (2021-2032)
- 7.2 North America Oncolytic Virus Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Oncolytic Virus Service Market Size by Country (2021-2026)
- 7.4 North America Oncolytic Virus Service Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Oncolytic Virus Service Market Size (2021-2032)
- 8.2 Europe Oncolytic Virus Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Oncolytic Virus Service Market Size by Country (2021-2026)
- 8.4 Europe Oncolytic Virus Service Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Oncolytic Virus Service Market Size (2021-2032)
- 9.2 Asia-Pacific Oncolytic Virus Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Oncolytic Virus Service Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Oncolytic Virus Service Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Oncolytic Virus Service Market Size (2021-2032)
- 10.2 South America Oncolytic Virus Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Oncolytic Virus Service Market Size by Country (2021-2026)
- 10.4 South America Oncolytic Virus Service Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Oncolytic Virus Service Market Size (2021-2032)
- 11.2 Middle East & Africa Oncolytic Virus Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Oncolytic Virus Service Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Oncolytic Virus Service Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Creative Biolabs
- 12.1.1 Creative Biolabs Company Information
- 12.1.2 Creative Biolabs Business Overview
- 12.1.3 Creative Biolabs Revenue in Oncolytic Virus Service Business (2021-2026)
- 12.1.4 Creative Biolabs Oncolytic Virus Service Product Portfolio
- 12.1.5 Creative Biolabs Recent Developments
- 12.2 Creative Biogene
- 12.2.1 Creative Biogene Company Information
- 12.2.2 Creative Biogene Business Overview
- 12.2.3 Creative Biogene Revenue in Oncolytic Virus Service Business (2021-2026)
- 12.2.4 Creative Biogene Oncolytic Virus Service Product Portfolio
- 12.2.5 Creative Biogene Recent Developments
- 12.3 Recipharm
- 12.3.1 Recipharm Company Information
- 12.3.2 Recipharm Business Overview
- 12.3.3 Recipharm Revenue in Oncolytic Virus Service Business (2021-2026)
- 12.3.4 Recipharm Oncolytic Virus Service Product Portfolio
- 12.3.5 Recipharm Recent Developments
- 12.4 Nabios
- 12.4.1 Nabios Company Information
- 12.4.2 Nabios Business Overview
- 12.4.3 Nabios Revenue in Oncolytic Virus Service Business (2021-2026)
- 12.4.4 Nabios Oncolytic Virus Service Product Portfolio
- 12.4.5 Nabios Recent Developments
- 12.5 IDT Biologika
- 12.5.1 IDT Biologika Company Information
- 12.5.2 IDT Biologika Business Overview
- 12.5.3 IDT Biologika Revenue in Oncolytic Virus Service Business (2021-2026)
- 12.5.4 IDT Biologika Oncolytic Virus Service Product Portfolio
- 12.5.5 IDT Biologika Recent Developments
- 12.6 FUJIFILM Diosynth Biotechnologies
- 12.6.1 FUJIFILM Diosynth Biotechnologies Company Information
- 12.6.2 FUJIFILM Diosynth Biotechnologies Business Overview
- 12.6.3 FUJIFILM Diosynth Biotechnologies Revenue in Oncolytic Virus Service Business (2021-2026)
- 12.6.4 FUJIFILM Diosynth Biotechnologies Oncolytic Virus Service Product Portfolio
- 12.6.5 FUJIFILM Diosynth Biotechnologies Recent Developments
- 12.7 Exothera
- 12.7.1 Exothera Company Information
- 12.7.2 Exothera Business Overview
- 12.7.3 Exothera Revenue in Oncolytic Virus Service Business (2021-2026)
- 12.7.4 Exothera Oncolytic Virus Service Product Portfolio
- 12.7.5 Exothera Recent Developments
- 12.8 Lonza
- 12.8.1 Lonza Company Information
- 12.8.2 Lonza Business Overview
- 12.8.3 Lonza Revenue in Oncolytic Virus Service Business (2021-2026)
- 12.8.4 Lonza Oncolytic Virus Service Product Portfolio
- 12.8.5 Lonza Recent Developments
- 12.9 ABL
- 12.9.1 ABL Company Information
- 12.9.2 ABL Business Overview
- 12.9.3 ABL Revenue in Oncolytic Virus Service Business (2021-2026)
- 12.9.4 ABL Oncolytic Virus Service Product Portfolio
- 12.9.5 ABL Recent Developments
- 12.10 Takara Bio
- 12.10.1 Takara Bio Company Information
- 12.10.2 Takara Bio Business Overview
- 12.10.3 Takara Bio Revenue in Oncolytic Virus Service Business (2021-2026)
- 12.10.4 Takara Bio Oncolytic Virus Service Product Portfolio
- 12.10.5 Takara Bio Recent Developments
- 12.11 Libentech
- 12.11.1 Libentech Company Information
- 12.11.2 Libentech Business Overview
- 12.11.3 Libentech Revenue in Oncolytic Virus Service Business (2021-2026)
- 12.11.4 Libentech Oncolytic Virus Service Product Portfolio
- 12.11.5 Libentech Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst